China Medical & HealthCare Group Limited provided earnings guidance for eleven months ended 30 November 2023. The Group is expected to record a profit attributable to Shareholders in the estimated range of approximately HKD 11 million to HKD 31 million for the eleven months ended 30 November 2023 as compared with (a) the loss for the corresponding period in 2022; and (b) the loss of approximately HKD 123.6 million for the year ended 31 December 2022. This was mainly due to (i) the increase in revenue from operations of the healthcare division amid the relaxation of epidemic preventive measures and the resumption of economic and social activities in the Peoples' Republic of China; (ii) the decrease in cost of medical consumables; and (iii) the increase in interest income from bank deposits but were partially off-set by (iv) the increase in cost of pharmaceutical and medicine; and (v) the increase in employee benefits expense.